OK Biotech Bilan de santé

Santé financière contrôle des critères 6/6

OK Biotech possède un total de capitaux propres de NT$2.5B et une dette totale de NT$420.2M, ce qui porte son ratio d'endettement à 17%. Son actif total et son passif total sont NT$3.6B et de NT$1.1B. L'EBIT de OK Biotech est NT$8.1M ce qui fait que son ratio de couverture des intérêts 24. Elle dispose de liquidités et de placements à court terme de NT$404.9M.

Informations clés

17.0%

Ratio d'endettement

NT$420.16m

Dette

Ratio de couverture des intérêts	24x
Argent liquide	NT$404.87m
Fonds propres	NT$2.47b
Total du passif	NT$1.08b
Total des actifs	NT$3.55b

Mises à jour récentes de la santé financière

OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

Mar 17

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Dec 08

Recent updates

OK Biotech's (TWSE:4155) Shareholders Have More To Worry About Than Lackluster Earnings

Aug 20

OK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend

Apr 26

Is OK Biotech Co., Ltd.'s (TPE:4155) Recent Price Movement Underpinned By Its Weak Fundamentals?

Feb 15

A Look At OK Biotech's (TPE:4155) Share Price Returns

Jan 31

We Wouldn't Rely On OK Biotech's (TPE:4155) Statutory Earnings As A Guide

Jan 17

Consider This Before Buying OK Biotech Co., Ltd. (TPE:4155) For The 5.4% Dividend

Jan 03

Estimating The Intrinsic Value Of OK Biotech Co., Ltd. (TPE:4155)

Dec 21

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Dec 08

Should You Be Impressed By OK Biotech's (TPE:4155) Returns on Capital?

Nov 23

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 4155 ( NT$1.5B ) dépassent ses passifs à court terme ( NT$866.1M ).

Passif à long terme: Les actifs à court terme de 4155 ( NT$1.5B ) dépassent ses passifs à long terme ( NT$213.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 4155 ( 0.6% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de 4155 a été réduit de 23.2% à 17% au cours des 5 dernières années.

Couverture de la dette: La dette de 4155 est bien couverte par le flux de trésorerie opérationnel ( 42.6% ).

Couverture des intérêts: Les paiements d'intérêts de 4155 sur sa dette sont bien couverts par l'EBIT ( 24 x couverture).

OK Biotech Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Recent updates

OK Biotech Co., Ltd. to Report Q3, 2024 Results on Nov 12, 2024

OK Biotech's (TWSE:4155) Shareholders Have More To Worry About Than Lackluster Earnings

Second quarter 2024 earnings released: EPS: NT$0.29 (vs NT$0.12 in 2Q 2023)

Dividend of NT$0.30 announced

Ok Biotech Co., Ltd. Announces Cash Dividend, Payable on September 27, 2024

OK Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024

OK Biotech Co., Ltd. Announces Change of Directors

First quarter 2024 earnings released: EPS: NT$0.25 (vs NT$0.16 in 1Q 2023)

OK Biotech Co., Ltd. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$0.02 (vs NT$1.37 in FY 2022)

OK Biotech Co., Ltd., Annual General Meeting, May 29, 2024

New minor risk - Profit margin trend

New minor risk - Market cap size

Upcoming dividend of NT$1.23 per share at 3.8% yield

Second quarter 2023 earnings released: EPS: NT$0.13 (vs NT$0.57 in 2Q 2022)

New major risk - Dividend sustainability

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: NT$1.51 (vs NT$0.46 in FY 2021)

Third quarter 2022 earnings released: EPS: NT$0.49 (vs NT$0.16 in 3Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$0.57 (vs NT$0.002 loss in 2Q 2021)

Upcoming dividend of NT$1.00 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued after recent price drop

Third quarter 2021 earnings released: EPS NT$0.16 (vs NT$0.30 in 3Q 2020)

Second quarter 2021 earnings released: NT$0.002 loss per share (vs NT$0.27 profit in 2Q 2020)

Upcoming dividend of NT$1.39 per share

First quarter 2021 earnings released: EPS NT$0.32 (vs NT$0.61 in 1Q 2020)

OK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend

Calculating The Fair Value Of OK Biotech Co., Ltd. (TPE:4155)

Full year 2020 earnings released: EPS NT$1.56 (vs NT$1.71 in FY 2019)

OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

OK Biotech Co., Ltd., Annual General Meeting, May 27, 2021

Has OK Biotech (TPE:4155) Got What It Takes To Become A Multi-Bagger?

Is OK Biotech Co., Ltd.'s (TPE:4155) Recent Price Movement Underpinned By Its Weak Fundamentals?

A Look At OK Biotech's (TPE:4155) Share Price Returns

We Wouldn't Rely On OK Biotech's (TPE:4155) Statutory Earnings As A Guide

New 90-day low: NT$26.45

Consider This Before Buying OK Biotech Co., Ltd. (TPE:4155) For The 5.4% Dividend

New 90-day low: NT$26.55

Estimating The Intrinsic Value Of OK Biotech Co., Ltd. (TPE:4155)

New 90-day low: NT$27.85

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Should You Be Impressed By OK Biotech's (TPE:4155) Returns on Capital?

Third quarter 2020 earnings released: EPS NT$0.30

Revenue and earnings miss expectations

New 90-day high: NT$31.70

New 90-day low - NT$26.05

First half earnings released

OK Biotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of TWD 34.268 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines